Literature DB >> 10230587

The visual results and changes in retinopathy in diabetic patients following cataract surgery.

S A Sadiq1, T Sleep, W M Amoaku.   

Abstract

INTRODUCTION: A study was designed to investigate the visual improvement and incidence of progression of retinopathy in diabetic patients following extracapsular cataract extraction or phacoemulsification. They were compared to a matched group of non-diabetic patients.
METHODS: A retrospective analysis of all diabetic patients (118) undergoing ECCE (90) or phacoemulsification (28) in 1995. These patients were operation and age matched with 118 non-diabetic patients who underwent surgery during the same year.
RESULTS: There was no statistically significant difference in complications following ECCE in diabetic and non-diabetic patients (p = 0.2). Complications were however more common in non-diabetic patients undergoing phacoemulsification compared to diabetics undergoing the same procedure (p = 0.046). Although consultants performed 42% of the surgery in diabetics compared to 31% in non-diabetics, there was no significant difference in the rate of complications between consultants and residents (p = 0.8). Overall the visual improvement in non-diabetics was better than diabetic patients (p = 0.006). This was due to a better improvement amongst non-diabetic patients undergoing phacoemulsification (p = 0.02). Overall, cataract surgery was found to lead to a worsening in retinopathy in 19 operated eyes (15 had no retinopathy preoperatively) compared to a worsening in 8 fellow eyes. This was statistically significant (p = 0.04). However, ECCE was no more likely to cause worsening of retinopathy than phacoemulsification (p = 0.87).
CONCLUSIONS: Diabetic patients due to undergo cataract surgery a) have a good chance of visual improvement but to a level less than if they were not diabetic, b) have a greater chance of visual loss, c) surgery may initiate or worsen any pre-existing retinopathy and this may affect their vision in the future.

Entities:  

Mesh:

Year:  1999        PMID: 10230587     DOI: 10.1177/112067219900900103

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  6 in total

Review 1.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

2.  The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract.

Authors:  Maged S Habib; Paul S Cannon; David H W Steel
Journal:  BMC Ophthalmol       Date:  2005-06-22       Impact factor: 2.209

3.  Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.

Authors:  Y Yang; C Bailey; F G Holz; N Eter; M Weber; C Baker; S Kiss; U Menchini; J M Ruiz Moreno; P Dugel; A Lotery
Journal:  Eye (Lond)       Date:  2015-06-26       Impact factor: 3.775

4.  The combination of phacoemulsification surgery and intravitreal triamcinolone injection in patients with cataract and diabetic macular edema.

Authors:  Ozlen Rodop Ozgur; Yelda Ozkurt; Zeynep Kulekci; Tufan Evciman
Journal:  Saudi J Ophthalmol       Date:  2015-10-30

Review 5.  Cataract surgery in diabetes mellitus: A systematic review.

Authors:  Aditya Kelkar; Jai Kelkar; Hetal Mehta; Winfried Amoaku
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

6.  Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery.

Authors:  Stamatina A Kabanarou; Tina Xirou; Eirini Boutouri; Ilias Gkizis; Dimitrios Vasilias; Georgios Bontzos; Irini Chatziralli
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.